Zhejiang Tailin Bioengineering Co Ltd

Zhejiang Tailin BioEngineering Co., Ltd. researches, develops, produces, and sells microbial detection, contamination control, process analysis, and inhibition protection products for the life sciences field in China and internationally. Its offerings include aseptic production and contamination control equipment, microbial testing products, and organic matter analysis technology products. The company also provides pharma processing solutions such as pharma isolators, high-precision filling and dispensing, sterile transfer, cell and gene therapy, radiopharma, laboratory animal, leak test systems, biodecontamination (including VH2O2 sterilization and dry fogging systems), sterilization monitoring and validation, microbiological testing (sterility and microbial limit test systems and pretreatment instruments), and water quality solutions (microbial monitoring, aquatic organism detection, total organic carbon analysis, enzyme substrate method, and automatic detection systems for cryptosporidium and giardia). Additionally, it offers filtration membranes (flat and blotting membranes, IVD series, membrane filters and dispensers) and analytical instruments (filter integrity testing, container closure integrity testers, water activity meters, and biodegradation analysis systems). Its products are used in biopharmaceuticals, medical and health care, laboratory animal research, food safety, disease control, water quality monitoring, and environmental protection. The company was formerly known as Hangzhou Tailin Biotechnology Equipment Co., Ltd. and changed its name to Zhejiang Tailin BioEngineering Co., Ltd. in April 2015. It was founded in 1993 and is based in Hangzhou, China.

300813.CS

Tailin Bio's 2026 interim net profit reaches 20.3728 million yuan

Tailin Bio has released its 2026 interim report. The company's total operating revenue was 165 million yuan, net profit attributable to the parent company was 20.3728 million yuan, and net cash inflow from operating activities was 21.1006 million yuan. The company's latest asset-liability ratio was 15.68 percent, up 0.85 percentage points from the previous quarter and up 3.10 percentage points from the same period last year. Gross margin was 49.02 percent, down 1.29 percentage points from the previous quarter and down 2.91 percentage points from the same period last year. Return on equity was 2.58 percent. Diluted earnings per share were 0.17 yuan, total asset turnover was 0.17 times, and inventory turnover was 0.64 times. The number of shareholders was 10,900, and the top ten shareholders held 62.36 percent of the total share capital.

300813.CS

Jiemian·23dRead more →

300813.CS▼

Tailin Bio Withdraws Convertible Bond Issuance Application, Shenzhen Stock Exchange Terminates Review

Zhejiang Tailin Bioengineering Co., Ltd. announced the withdrawal of its application to issue convertible corporate bonds to unspecified investors, and the Shenzhen Stock Exchange has decided to terminate the review of the application. The company held a board meeting on August 14, 2026, approving the termination of the issuance and the withdrawal of application documents, and subsequently submitted the withdrawal application to the Shenzhen Stock Exchange together with its sponsor, Great Wall Securities. In accordance with relevant regulations, the Shenzhen Stock Exchange formally issued a decision to terminate the review on August 24, 2026.

300813.CS ▼

Jiemian·26dRead more →